Viracta Therapeutics, Inc. Profile Avatar - Palmy Investing

Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase…

Biotechnology
US, Cardiff-by-the-Sea [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Viracta Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Viracta Therapeutics, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Viracta Therapeutics, Inc..

End of VIRX's Analysis
CIK: 1061027 CUSIP: 92765F108 ISIN: US92765F1084 LEI: - UEI: -
Secondary Listings
VIRX has no secondary listings inside our databases.